NanoLogix is very pleased to announce that today we have been informed by Faisal Alharthi, CEO of the Nasaem AlJazira Co., that the Saudi Arabia FDA (SFDA) has approved our products for import to and use in The Kingdom of Saudi Arabia. This approval came after many months of extensive testing of our products in Saudi Arabia and diligent pursuit of the approval by the Nasaem AlJazira Co. The process required a large expenditure on the part of the Nasaem AlJazira Co., multiple trips to the United States, and multiple trips by NanoLogix management to Washington DC for required approvals from the US Department of State and the Embassy of the Kingdom of Saudi Arabia.
Assignment changes hands all the time. Sure it might be a little bit odd that it was changed to Bret, but not exactly unheard of since he was listed as the sole inventor.
It is possible that the assignment was made as a form of compensation instead of monetary compensation. It is also very possible that the invention was made on his own time, off-site, without company resources and it is rightfully his (even if many others would have given it to their company out of principle).
This is the only one which is in his name, and there are many others out there which are not. So without knowing the details, no conclusions can be made.
You are right. Any time that anybody mentions a company and "resources" it can only mean money. Thank you for correcting me from my erroneous ways.
You really must be a treat to those around you. Is that why you spend Christmas alone?
Did I say "cash resources"? No, I did not. But that would not allow you the opportunity to disparage the company so you have to make up a new meaning to my comment. It really is sick how far you go to get negative jabs in on every single post.
Good to see the old products are still updating. For a while I was wondering if they had put all their resources into the n-assay.
NanoLogix has received notification of BNP patent grant from the European Union. Grant date was 11/26/2014. This is a welcome addition to the NanoLogix patent portfolio, providing intellectual property protection in the EU for the first time for any NanoLogix product. Interested shareholders should note the length of time from date of application to date of patent grant. Over 6-1/2 years of legal and financial resources went into this achievement. The company thanks Gwen Acker Wood, PhD, JD, of ACKER WOOD Intellectual Property Law, LLC, for her outstanding work on this and other patents pending and granted.
EUROPEAN PATENT GRANT CERTIFICATE _____________________________________________________________
Applicant Nanologix, Inc. Application Date 24 March 2008 Grant No 2134857 Grant Date 26 November 2014 Expiry Date 24 March 2028 (If renewed as set out below) Title Detection and identification of microorganisms on transparent permeable membranes Priority Application(s) United States of America Application No. 60/896321 filed on 22nd March 2007 Renewal Fees Due Annually in each designated state in March
And AMZN needs to make something like $700B in order to justify its price.
A board favorite around here, AXDX would need somewhere around $800M instead of the $50K or whatever it makes.
Your "valuation" is pointless.
That was 95% of their bashing. "Where are the financials? What are they hiding? They must be hemorrhaging money if they won't release numbers." etc.
Now they have nothing left. Give them 24 hours and they will be back to personal attacks on the CEO.
This was provided to everyone who signs up for their email updates. It was written by the company themselves and sent to everyone on their list.
This update is related to the Press Release issued by NanoLogix 14 October 2014
At a minimum, the press release has been covered with stories in the Washington Post Innovation blog, The Warren Tribune Chronicle, Warren, Ohio; The YoungstownCBS/Fox/ABC/NBC Youngstown, Ohio affiliated television stations; NBC/Pittsburgh, Fox/Tampa television.
As a result, NanoLogix N-Assay (V) is currently being evaluated by pharmaceutical companies for use as a simple rapid diagnostic tool for viruses for use in remote locations in close proximity to outbreak events. Nanologix this week signed two Mutual Confidentiality Agreements with US corporations interested in their technology.
Given the key word "Confidentiality", further information will be released when and if dictated by events.
HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”
The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.
Supporting information on the N-Assay (B), used for bacterial detection and identification and evidence of the capabilities of one version of the technology can be found by following this link:
etc. etc. look online for it